DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Acelyrin - 1 Acelyrin's izokibep - 1 Hidradenitis - 1 Piper Sandler - 1 Jefferies - 1 Akash Tewari - 1 We'll - 1 Christy Santhosh - 1
Top related locs:
Acelyrin Bengaluru
Top related orgs:
Ventyx Biosciences - 1 Apogee Therapeutics - 1 Thomson - 1

Search resuls for: "Ventyx Biosciences"


2 mentions found


☆ Acelyrin's skin disease drug trial failure wipes off IPO gains
  + stars: | 2023-09-12 | by ( Christy Santhosh | ) www.reuters.com   time to read: +2 min
Sept 12 (Reuters) - Shares of drug developer Acelyrin (SLRN.O) on Tuesday erased all gains made since their stellar market debut in May, as the company's experimental lead drug failed to show superiority to placebo in reducing symptoms of an inflammatory skin disease. HS is a chronic inflammatory skin condition that causes painful lumps under the skin. Acelyrin said the trial was hit by early discontinuations as well as better placebo efficacy rates. However, Jefferies analyst Akash Tewari slashed the price target on Acelyrin's stock to $15 from $31, calling the latest data "painfully disappointing." "It's difficult to glean much from the data given how poorly the trial was run.
Persons: Acelyrin, Acelyrin's izokibep, Hidradenitis, Piper Sandler, Jefferies, Akash Tewari, We'll, Christy Santhosh, Saumyadeb Chakrabarty Organizations: Ventyx Biosciences, Apogee Therapeutics, Thomson Locations: Acelyrin, Bengaluru
☆ Goldman Sachs says this little-known biotech stock can jump more than 50%
  + stars: | 2022-12-19 | by ( Sarah Min | ) www.cnbc.com   time to read: +1 min
Shares of Ventyx Biosciences could surge more than 50% on a competitive slate of treatments for autoimmune diseases, according to Goldman Sachs. Analyst Chris Shibutani initiated coverage of Ventyx Biosciences with a buy rating, saying the company has a promising new oral treatment in development for plaque psoriasis. The TYK2 inhibitor from Ventyx Biosciences is notable, because it's expected to have "one of the cleanest safety profiles" among its competitors. "Commercially, VTX958 is being developed for large, well-established I & I markets that generate tens of billions of dollars in annual sales," Shibutani wrote. Shares of Ventyx Biosciences have surged more than 60% in 2022.
0 next >>
Total: 2